Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience

Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder

(2018) Patrick J. Hensley et al.   Clinical Genitourinary Cancer

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

(2017) Philippe E. Spiess et al.   Journal of the National Comprehensive Cancer Network

Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer

(2017) Meera R. Chappidi et al.   UROLOGY

Impact of suboptimal neoadjuvant chemotherapy on peri-operative outcomes and survival after robot-assisted radical cystectomy: a multicentre multinational study

(2016) Nobuyuki Hinata et al.   BJU INTERNATIONAL

Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?

(2016) Homayoun Zargar et al.   JOURNAL OF UROLOGY

Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

(2015) Homayoun Zargar et al.   EUROPEAN UROLOGY

Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes

(2015) Nilay M. Gandhi et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin

(2015) Elisabeth E. Fransen van de Putte et al.   WORLD JOURNAL OF UROLOGY

A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma

(2014) Maha Hussain et al.   CANCER

Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates

(2014) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation of Pathologic Complete Response with Survival After Neoadjuvant Chemotherapy in Bladder Cancer Treated with Cystectomy: A Meta-analysis

(2013) Fausto Petrelli et al.   EUROPEAN UROLOGY

Trends in the Utilization of Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Results From the National Cancer Database

(2013) Harras B. Zaid et al.   UROLOGY

Pathologic Downstaging Is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Urothelial Bladder Cancer

(2011) Robert Rosenblatt et al.   EUROPEAN UROLOGY

Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer

(2010) Ganesh V. Raj et al.   CANCER

Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy

(2009) Guru Sonpavde et al.   CANCER

Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the Bladder

(2008) David C. Smith et al.   JOURNAL OF UROLOGY